Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.84
RGLS's Cash-to-Debt is ranked lower than
64% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. RGLS: 3.84 )
Ranked among companies with meaningful Cash-to-Debt only.
RGLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.81  Med: 9.68 Max: No Debt
Current: 3.84
Equity-to-Asset 0.56
RGLS's Equity-to-Asset is ranked lower than
64% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RGLS: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
RGLS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.97  Med: 0.68 Max: 0.88
Current: 0.56
-0.97
0.88
Piotroski F-Score: 1
Altman Z-Score: -4.38
Beneish M-Score: -6.17
WACC vs ROIC
16.94%
-3020.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -6825.88
RGLS's Operating Margin % is ranked lower than
90% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. RGLS: -6825.88 )
Ranked among companies with meaningful Operating Margin % only.
RGLS' s Operating Margin % Range Over the Past 10 Years
Min: -6825.96  Med: -180.19 Max: -51.76
Current: -6825.88
-6825.96
-51.76
Net Margin % -6853.94
RGLS's Net Margin % is ranked lower than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. RGLS: -6853.94 )
Ranked among companies with meaningful Net Margin % only.
RGLS' s Net Margin % Range Over the Past 10 Years
Min: -6853.94  Med: -180.9 Max: -55.13
Current: -6853.94
-6853.94
-55.13
ROE % -91.23
RGLS's ROE % is ranked lower than
77% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. RGLS: -91.23 )
Ranked among companies with meaningful ROE % only.
RGLS' s ROE % Range Over the Past 10 Years
Min: -169.02  Med: -50.28 Max: -24
Current: -91.23
-169.02
-24
ROA % -66.42
RGLS's ROA % is ranked lower than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. RGLS: -66.42 )
Ranked among companies with meaningful ROA % only.
RGLS' s ROA % Range Over the Past 10 Years
Min: -67.7  Med: -35.57 Max: -16.48
Current: -66.42
-67.7
-16.48
ROC (Joel Greenblatt) % -670.89
RGLS's ROC (Joel Greenblatt) % is ranked lower than
56% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. RGLS: -670.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RGLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1544.17  Med: -592.79 Max: -450.68
Current: -670.89
-1544.17
-450.68
3-Year Revenue Growth Rate -64.40
RGLS's 3-Year Revenue Growth Rate is ranked lower than
87% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. RGLS: -64.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RGLS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -77 Max: -36.1
Current: -64.4
3-Year EBITDA Growth Rate 49.00
RGLS's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. RGLS: 49.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RGLS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.25 Max: 49
Current: 49
0
49
3-Year EPS without NRI Growth Rate 46.80
RGLS's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. RGLS: 46.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RGLS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -47.7 Max: 46.8
Current: 46.8
0
46.8
GuruFocus has detected 4 Warning Signs with Regulus Therapeutics Inc $RGLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RGLS's 10-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q3 2016

RGLS Guru Trades in Q3 2016

Jim Simons 645,000 sh (New)
» More
Q4 2016

RGLS Guru Trades in Q4 2016

Paul Tudor Jones 46,688 sh (New)
Jim Simons 321,200 sh (-50.20%)
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ZSAN, AMEX:SYN, OTCPK:BBLG, OTCPK:ZLDAF, NAS:CFRX, NAS:IPCI, NAS:ARQL, NAS:ALDX, NAS:KALV, OTCPK:AAVXF, NAS:CAPR, NAS:KMPH, NAS:XENE, NAS:VSTM, OTCPK:SLNCF, NAS:DRNA, OTCPK:SVACD, NAS:NTEC, NAS:TTNP, NAS:GTXI » details
Traded in other countries:7RG.Germany,
Headquarter Location:USA
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases.

Regulus Therapeutics is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Top Ranked Articles about Regulus Therapeutics Inc

RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017
DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Regulus Therapeutics, Inc. (“Regulus” or the “Company”) (NASDAQ:RGLS) of the April 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all those who purchased Regulus stock or options between January 21, 2016 and June 27, 2016 (the “Class Period”).  The case, Jin v. Regulus Therapeutics Inc. et al, No. 17-cv-00267 was filed on February 10, 2017, and has been assigned to Judge Barry Ted Moskowitz. The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose safety concerns regarding its lead product candidate, RG-101, for the treatment of hepatitis C virus (HCV) infection. First, during a webcast and conference call to present additional interim data on RG-101 at the International Liver Conference on April 15, 2016, the Company disclosed in a footnote that the Daklinza arm of the RG-101 Phase II trial had a severe adverse event from jaundice.  Then, on June 27, 2016, FDA informed Regulus that it would place for RG-101 on full clinical hold after a second serious adverse event of jaundice was reported.  After these safety concerns were announced, the stock declined severely, damaging investors. Finally, on January 27, 2017, the Company announced that it would submit a complete response to the FDA with the requested information in the fourth quarter of 2017 and stated that there can be “no assurances as to when the clinical hold on RG-101 may be lifted, if at all.” After the announcement, Regulus’s share price fell from $2.25 per share on January 27, 2017 to a closing price of $1.30 on January 30, 2017—a $0.95 or a 42.2% drop. Request more information now by clicking here: www.faruqilaw.com/RGLS. There is no cost or obligation to you. Take Action You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Regulus’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.


Read more...
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
LOS ANGELES, March 30, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ:RGLS) concerning possible violations of federal securities laws between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 3, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.According to the Complaint, throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported. When this information was released, the stock price of Regulus fell, causing investors harm.Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/


Read more...
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline - April 3, 2017

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Regulus Therapeutics Inc.  (“Regulus” or the “Company”) (NASDAQ:RGLS) and certain of its officers, on behalf of a class who purchased Regulus securities between January 21, 2016 and January 27, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rgls. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Regulus business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) patients treated with RG-101 were at higher risk of contracting jaundice; (2) as a result, Regulus had exaggerated RG-101’s approval prospects and/or commercial sustainability; and (3) consequently, Regulus’s public statements were materially false and misleading at all relevant times. On June 27, 2016, Regulus released that it had received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported. Following this news, Regulus dropped $2.47 per share, or over 49%, to close at $2.54 on June 28, 2016. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/rgls or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ:RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to:http://www.zlk.com/pslra/regulus-therapeutics?wire-3or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events (“SAE”) were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S. Food and Drug Administration (“FDA”) to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants’ statements about Regulus’ business and prospects were false and misleading and/or lacked a reasonable basis.Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – RGLS

NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ:RGLS) and certain of its officers.  The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Regulus securities between January 21, 2016 and June 27, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Regulus securities during the Class Period, you have until April 3, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Regulus is a biopharmaceutical company that focuses on the discovery and development of drugs that target microRNAs to treat and prevent various diseases, including hepatitis C infections, cardiovascular, fibrosis, oncology, immune-inflammatory, and metabolic diseases.  One of its main clinical development products is RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) patients treated with RG-101 were at increased risk of contracting jaundice; (ii) consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, Regulus’s public statements were materially false and misleading at all relevant times. On June 27, 2016, post-market, Regulus announced that it had received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed RG-101 on clinical hold after a second serious adverse event of jaundice was reported in a patient treated with the drug.  On this news, Regulus’s share price fell $2.47, or more than 49%, to close at $2.54 on June 28, 2016.   The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.47
RGLS's PB Ratio is ranked higher than
81% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. RGLS: 1.47 )
Ranked among companies with meaningful PB Ratio only.
RGLS' s PB Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.55 Max: 12.95
Current: 1.47
1.04
12.95
PS Ratio 70.45
RGLS's PS Ratio is ranked lower than
82% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. RGLS: 70.45 )
Ranked among companies with meaningful PS Ratio only.
RGLS' s PS Ratio Range Over the Past 10 Years
Min: 0.1  Med: 19.79 Max: 115.91
Current: 70.45
0.1
115.91
EV-to-EBIT -0.50
RGLS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. RGLS: -0.50 )
Ranked among companies with meaningful EV-to-EBIT only.
RGLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.9  Med: -6.4 Max: 3.1
Current: -0.5
-24.9
3.1
EV-to-EBITDA -0.51
RGLS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. RGLS: -0.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.9  Med: -6.6 Max: 3.2
Current: -0.51
-25.9
3.2
Current Ratio 6.34
RGLS's Current Ratio is ranked higher than
65% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. RGLS: 6.34 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 3.01  Med: 7.05 Max: 11.3
Current: 6.34
3.01
11.3
Quick Ratio 5.93
RGLS's Quick Ratio is ranked higher than
63% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. RGLS: 5.93 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 3.01  Med: 6.84 Max: 11.3
Current: 5.93
3.01
11.3
Days Sales Outstanding 506.54
RGLS's Days Sales Outstanding is ranked lower than
98% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. RGLS: 506.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 94.62 Max: 506.54
Current: 506.54
1.47
506.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.20
RGLS's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. RGLS: -8.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -719.3  Med: -10.95 Max: 0
Current: -8.2
-719.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.58
RGLS's Price-to-Net-Cash is ranked higher than
79% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. RGLS: 2.58 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RGLS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.25  Med: 3.99 Max: 6.52
Current: 2.58
2.25
6.52
Price-to-Net-Current-Asset-Value 1.91
RGLS's Price-to-Net-Current-Asset-Value is ranked higher than
86% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. RGLS: 1.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RGLS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.67  Med: 3.91 Max: 6.27
Current: 1.91
1.67
6.27
Price-to-Tangible-Book 1.49
RGLS's Price-to-Tangible-Book is ranked higher than
85% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. RGLS: 1.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RGLS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.3  Med: 3.7 Max: 6
Current: 1.49
1.3
6
Price-to-Median-PS-Value 3.52
RGLS's Price-to-Median-PS-Value is ranked lower than
92% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. RGLS: 3.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RGLS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.09 Max: 5.11
Current: 3.52
0.01
5.11
Earnings Yield (Greenblatt) % -202.82
RGLS's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. RGLS: -202.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RGLS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -290.34  Med: 39.35 Max: 44.4
Current: -202.82
-290.34
44.4

More Statistics

Revenue (TTM) (Mil) $1.19
EPS (TTM) $ -1.55
Beta2.55
Short Percentage of Float9.25%
52-Week Range $0.94 - 6.42
Shares Outstanding (Mil)52.93

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 0 0
EPS ($) -1.05 -1.10 -1.27
EPS without NRI ($) -1.05 -1.10 -1.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017 Apr 27 2017 
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulu Mar 31 2017 
RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving R Mar 31 2017 
DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutic Mar 31 2017 
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulu Mar 30 2017 
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therap Mar 30 2017 
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulu Mar 30 2017 
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf Mar 28 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regu Mar 17 2017 
Top Insider Buys, Sells of the Week Feb 26 2016 

More From Other Websites
Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017 Apr 27 2017
DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 31 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in... Mar 31 2017
DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Mar 31 2017
RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 31 2017
DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 31 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In... Mar 31 2017
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Mar 30 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Mar 30 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 30 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus... Mar 28 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf... Mar 28 2017
Regulus to Present at the 16th Annual Needham Healthcare Conference Mar 28 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus... Mar 27 2017
Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics Mar 27 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on... Mar 24 2017
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 24 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 24 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics... Mar 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)